Nephrology

Myles Selig Wolf, MD

Professor of Medicine
Charles Johnson, M.D. Distinguished Professor of Medicine
Chief of Nephrology
Professor in Population Health Sciences
Member of the Duke Clinical Research Institute
Email address myles.wolf@duke.edu
Fax: 919-684-3011

The focus of my research is disordered mineral metabolism across the spectrum of chronic kidney disease, including dialysis, kidney transplantation and earlier stages.

My research has been published in leading general medicine and subspecialty journals, including the New England Journal of Medicine, JAMA, the Journal of Clinical Investigation, Circulation, Cell Metabolism, Journal of the American Society of Nephrology, and Kidney International, among others.

My primary contributions have been in the area of hormonal regulation of phosphate homeostasis. I have helped to characterize the physiological role of fibroblast growth factor 23 in health and in chronic kidney disease, and the impact of elevated fibroblast growth factor 23 levels on adverse clinical outcomes in patients with kidney disease.

Education and Training

  • Research Fellowship in Nephrology, Massachusetts General Hospital, 2000 - 2001
  • Clinical Fellowship in Nephrology, Brigham and Women's Hospital, 1999 - 2000
  • Internal Medicine Residency, Massachusetts General Hospital, 1996 - 1999
  • M.Med.Sc., Harvard Medical School, 2002
  • M.D., State University of New York, Brooklyn, 1996

Grants

Publications

Babitt, Jodie L., Michele F. Eisenga, Volker H. Haase, Abhijit V. Kshirsagar, Adeera Levin, Francesco Locatelli, Jolanta Małyszko, et al. “Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.” In Kidney Int, 99:1280–95, 2021. https://doi.org/10.1016/j.kint.2021.03.020.

PMID
33839163
Full Text

Edmonston, Daniel L., Tamara Isakova, Laura M. Dember, Steven Brunelli, Amy Young, Rebecca Brosch, Srinivasan Beddhu, Hrishikesh Chakraborty, and Myles Wolf. “Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.” Am J Kidney Dis 77, no. 6 (June 2021): 920-930.e1. https://doi.org/10.1053/j.ajkd.2020.10.008.

PMID
33279558
Full Text

Bansal, Nisha, Leila R. Zelnick, Elsayed Z. Soliman, Amanda Anderson, Robert Christenson, Christopher DeFilippi, Rajat Deo, et al. “Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.” Am J Kidney Dis 77, no. 6 (June 2021): 907–19. https://doi.org/10.1053/j.ajkd.2020.09.021.

PMID
33309861
Full Text

Bello, A. K., M. McIsaac, I. G. Okpechi, D. W. Johnson, V. Jha, D. C. H. Harris, S. Saad, et al. “International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean.” Kidney International Supplements 11, no. 2 (May 1, 2021): e66–76. https://doi.org/10.1016/j.kisu.2021.01.001.

Full Text

Schaefer, Benedikt, Moritz Tobiasch, André Viveiros, Herbert Tilg, Nicholas A. Kennedy, Myles Wolf, and Heinz Zoller. “Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.” Br J Clin Pharmacol 87, no. 5 (May 2021): 2256–73. https://doi.org/10.1111/bcp.14643.

PMID
33188534
Full Text

Gitomer, Berenice, Renata Pereira, Isidro B. Salusky, Jason W. Stoneback, Tamara Isakova, Xuan Cai, Lorien S. Dalrymple, et al. “Mineral bone disease in autosomal dominant polycystic kidney disease.” Kidney Int 99, no. 4 (April 2021): 977–85. https://doi.org/10.1016/j.kint.2020.07.041.

PMID
32926884
Full Text

Ghuman, Jasleen, Xuan Cai, Ravi B. Patel, Sadiya S. Khan, Jonathan Hecktman, Margaret M. Redfield, Gregory Lewis, et al. “Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.” J Card Fail 27, no. 3 (March 2021): 309–17. https://doi.org/10.1016/j.cardfail.2020.09.477.

PMID
33035687
Full Text

Bhandari, Sunil, Philip A. Kalra, Mario Berkowitz, Diogo Belo, Lars L. Thomsen, and Myles Wolf. “Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.” Nephrol Dial Transplant 36, no. 1 (January 1, 2021): 111–20. https://doi.org/10.1093/ndt/gfaa011.

PMID
32049331
Full Text

Pages